Detalhe da pesquisa
1.
Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias.
Br J Haematol
; 204(4): 1325-1334, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462984
2.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
3.
CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
Ann Hematol
; 103(1): 73-88, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37917373
4.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
5.
Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosis.
Haematologica
; 108(11): 3068-3085, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317877
6.
The aetiology and burden of myeloproliferative neoplasms in the United Kingdom: the MyelOproliferative neoplasmS: an In-depth case-control (MOSAICC) study protocol.
BMC Cancer
; 23(1): 1207, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38062390
7.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
8.
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Br J Haematol
; 192(1): 62-74, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449159
9.
Significance of NPM1 Gene Mutations in AML.
Int J Mol Sci
; 22(18)2021 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34576201
10.
Second cancers in MPN: Survival analysis from an international study.
Am J Hematol
; 95(3): 295-301, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816122
11.
The management of myelofibrosis: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 136-150, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38037886
12.
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 127-135, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932932
13.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Blood
; 130(17): 1889-1897, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074595
14.
The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples.
Ann Hum Genet
; 82(2): 114-118, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29076129
15.
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
J Transl Med
; 16(1): 360, 2018 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30558676
16.
Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series.
Thromb J
; 16: 33, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30574023
17.
Epigenetics in Myeloproliferative Neoplasms.
J Cell Mol Med
; 21(9): 1660-1667, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677265
18.
Ruxolitinib: gaining more than intended.
Blood
; 135(13): 983-984, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32219353
19.
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Blood
; 125(19): 2923-32, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805811
20.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Blood
; 125(25): 3878-85, 2015 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833957